Office of Population, Censuses, and Surveys. Cancer Registry, Welsh Office: HMSO, 1980
2.
ViadanaEBrossIDJPickrenJW. The metastatic spread of cancers of the digestive system in man. Oncology1978; 35: 114–26
3.
WelchJPDonaldsonGA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg1979; 189: 496–502
4.
DalyJMButlerJKemenyNYehSJRidgeJABotetJBadingJRDeCosseJJBenuaRS. Predicting tumour response in patients with colorectal hepatic metastases. Cancer1985; 202: 384–93
5.
BrossIDBlumensonLE. Metastatic sites that produce generalized cancer: Identification and kinetics of generalizing sites. In: WeissL ed. Fundamental aspects of metastasis.Amsterdam: North Holland, 1976: 359–75.
6.
JaffeBMDoneganWRWatsonFSprattJS. Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet1968; 127: 1–11
7.
WagnerJSAdsonMAVan HeerdenJAAdsonMHIlstrupDM. The natural history of hepatic metastases from colorectal cancer. Ann Surg1984; 199: 502–8
8.
FortnerJGSilvaJSGolbeyRBCoxEBMacleanBJ. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. 1: Treatment by hepatic resection. Ann Surg1983; 199: 306–16
9.
AugustDAOttowRTSugarbakerPH. Clinical perspective of human colorectal cancer metastasis. Canc Met Rev1984; 3: 303–24
10.
Department of Health and Social Security, Form SH3 regional and national summaries for 1980. LondonDHSS, 1981
11.
CarterSK. Large bowel cancer: The current status of treatment. J Nat Canc Inst1976; 56: 3–10
12.
KemenyNYagodaABraunD.Metastatic colorectal carcinoma. A prospective randomised trial of methyl CCNU, 5-fluorouracil (5FU) and vincristine (MOF) vs MOF plus streptozatocin(MOF strep). Cancer1983; 5120–4
13.
KemenyNDalyJReichmanBGellerNBotetJOdermanP.Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med1987; 107: 459–65
14.
Allen-MershTGKemenyNNiedzwieckiDShurgotBDalyJM. Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut1987; 28: 1625–9
15.
EnsmingerWDRosowskiARasoV. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2-deoxyuridine and 5-fluorouracil. Cancer Res1978; 38: 3784–92.
16.
FreiE.Effect of dose and schedule on response. In: HollandJFFreiE, eds. Cancer medicine.Philadelphia: Lea & Febiger, 1973: 717–30
TaylorIMachinDMulleeMTrotterGCookeTWestC.A randomised controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. B J Surg1985; 72: 359–63
19.
AnsfieldFJRamirezGDavisHLWirtanenGWJohnsonROBryanGTManaloFBBordenECDavisTEEsmailiM.Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer1975; 36: 2413–7
20.
CadyBOberfieldRA. Regional infusion chemotherapy Of hepatic metastases from carcinoma of the colon. Am J Surg1974; 127: 220–7
21.
CadyB.Hepatic arterial patency and complications after catheterisation and infusion chemotherapy. Ann Surg1973; 178: 156–61
22.
BalchCMUristMMSeng-JawSMcGregorM.A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg1983; 198: 567–73
23.
CohenAMKaufmanSDWoodWC. Treatment of colorectal cancer hepatic metastases by hepatic artery chemotherapy. Dis Colon Rectum1985; 28: 389–93
24.
NiederhuberJEnsmingrWGyvesJThrallJWalkerSCozziE.Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer1984; 53: 1336–43
25.
BalchCMUristMMMcGregorML. Continuous regional chemotherapy for metastatic colorectal cancer using a totally implantable infusion pump. Am J Surg1983; 14: 285–90
26.
HohnDCRaynerAAEconomouJIgnoffoRJLewisBJStaggRJ. Toxicities and complications of implanted pump hepatic arterial and intravenous infusion. Cancer1986; 57: 465–9
27.
StollBA. Balancing cost and benefit in treatment of late cancer. Lancet1988; i: 579–80
